Home
overview
During the last decade major progress has been made in understanding neurodegenerative diseases, both at clinical and scientific levels. Advances in understanding pathophysiologic mechanisms have resulted in a wide array of novel treatment approaches. There is now a real potential to develop therapies which will slow, and possibly stop many of these conditions

New Directions in Neurodegenerative Drug Discovery & Development will explore the development of new technologies to design and treat neurodegenerative disorders, including Alzheimer’s, Parkinson’s and Huntingdon’s disease. You will hear evidence for new drug targets in neurodegenerative disorders and how the latest developments in neurodegenerative drug discovery will impact on the pharmaceutical market. The conference will also address how these novel therapies may be utilised as the next generation of therapeutic drugs.

Why should you attend this event? This comprehensive conference is organised and produced by SMi: we have identified protein manufacturing as a targeted sector for executives anxious to keep a close eye on industry development. As a key industry representative, you are aware of the need to keep updated on developments that will increase both your efficiency and productivity. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Amaud Ythier

Dr Amaud Ythier, Vice President, Neurology Research and Development, Serono International

9:10 GREYING OF THE POPULATION

Dr Gavin Kilpatrick

Dr Gavin Kilpatrick, Research Director, CeNeS

  • Increased life expectancy and increased quality of life expectancy
  • The cost to society of neurodegenerative disorders
  • Market size for new neuroprotective agents
  • Current therapies vs medical need
  • Overview of the development pipeline for neurodegenerative disorders
  • 9:40 QUENCHING INFLAMMATION IN THE AD BRAIN

    Dr Matt Sadler

    Dr Matt Sadler, Vice President, Research, Immune Network

  • The involvement of neuroinflammation in AD pathology
  • Current molecular targets and approaches for drugs to block neuroinflammation
  • Clinical experience to date with anti-inflammatory drugs
  • The “vaccine” approach, can we convince microglia to be our friends?
  • Other approaches to AD therapy: prospects for drug cocktails
  • Slowing AD progression: social and pharmacoeconomic impact
  • 10:20 CHRONIC IN VIVO MODELS FOR PHARMACOLOGICAL TESTING

    Dr Rudolf Urbanics

    Dr Rudolf Urbanics, Deputy Research and Development Director, Biorex

  • Genetic rodent models for Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD)
  • Chronic low level exposure to toxins may lead to chronic neurodegeneration-
  • Role of partial inhibition of mitochondrial electron chain in oxidative damage
  • Possible therapeutic role of Heat Shock Proteins in neurodegenerative diseases
  • 11:00 Morning Coffee

    11:20 PRECLINICAL PHARMACOLOGY OF RILUZOLE IN PARKINSON’S DISEASE

    Dr Georg Andrees Bohme

    Dr Georg Andrees Bohme, Head, Neurophysiology, Neurodegenerative Disease Group, Aventis

  • Excitoxicity in Parkinson’s disease
  • Mechanism of action of riluzole
  • Effect of riluzole and primate models of Parkinson’s disease
  • 12:00 NOVEL TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH NERVE REGENERATION

    Dr Scott Wieland

    Dr Scott Wieland, Vice President, Product Development and Regulatory Affairs, NeoTherapeutics

  • The role of beta amyloids in the formation of plaques
  • How NeotrofinTM effects the processing of the amyloid precursor protein
  • Phase II Clinical trial results for the drug NeotrofinTM
  • What is the development potential of NeotrofinTM
  • 12:40 Networking Lunch

    14:00 HUMAN NEURAL STEM CELL TRANSPLANTATION

    Dr Helen Hodges

    Dr Helen Hodges, Founder Member and Consultant, ReNeuron

  • Properties and advantages of stem cell transplantation in the CNS
  • What is the therapeutic potential for stem cell lines?
  • Preclinical evidence for therapeutic efficacy
  • Possible mechanisms of action of stem cell grafts
  • 14:40 NMDA ANTAGONISTS AND NEURODEGENERATION

    Dr Michael Snape

    Dr Michael Snape, Principal Scientist, Vernalis

  • NMDA antagonists – efficacy in neurodegeneration
  • NMDA antagonists - tolerability
  • Pre-clinical differentiation of well-tolerated NMDA antagonists for the treatment of neurodegeneration
  • 15:20 Afternoon Tea

    15:40 NEXT GENERATION ACETYLCHOLINE INHIBITORS

    Dr Luc Truyen

    Dr Luc Truyen, Global Medical Leader for Reminyl, Janssen Research Foundation

  • What is the need for new treatments for Alzheimer's in the current market?
  • What is the efficacy of Reminyl® and how was this measured?
  • Mechanism of action of Reminyl®
  • What are the future development plans for this drug?
  • 16:20 POTENTIAL THERAPEUTICS FOR MILD COGNITIVE IMPAIRMENT (MCI)

    Dr Vincent Simmon

    Dr Vincent Simmon, President, Cortex Pharmaceuticals

  • The focus of existing therapeutics
  • The use of functional imaging studies to study glutamate transmission
  • Experiences at Cortex - AMPAKINE®CX516 in clinical studies
  • 17:00 Chairman's Closing Remarks and Close of Day One

    17:10 Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Peter Mathisen

    Dr Peter Mathisen, Head, Cell Models, CNS Research, Aventis

    9:10 THE APPLICATION OF IMAGING TO THE DEVELOPMENT OF THE APPLICATION OF IMAGING TO THE DEVELOPMENT OF NEURODEGENERATIVE DRUGS

    Professor David Brooks

    Professor David Brooks, , IRSL

  • The clinical assessment of disease progression uses subjective rating scales and is confounded by various effects
  • Imaging provides the possibility of using a range of objective biomarkers of structural and functional changes in the target organ.
  • Imaging looks at the metabolic, pharmacologic and immune changes associated with degenerative diseases
  • Examples of the application of imaging to drug development will be shown
  • 9:40 TRANSGENIC ANIMAL MODELS

    Dr Guy Seabrook

    Dr Guy Seabrook, Senior Research Fellow, Merxk Sharp and Dohme Research Laboratories

  • What is the impact of gene disruption and transgenic technology in neurodegenerative research
  • Amyloid precursor protein and presenilin knockouts
  • Transgenes linked to familial early onset AD
  • Development of new strains relevant to Alzheimer's Disease
  • Conditional transgenics
  • 10:20 CELL THERAPY FOR PARKINSON'S DISEASE

    Dr Louis Bucalo

    Dr Louis Bucalo, President and CEO, Titan Pharmaceuticals

  • Current dopaminergic based therapy for Parkinson’s based on: -Effectiveness -Side effects
  • What is Spheramine and how does it work?
  • What are the Phase I/II results for Spheramine?
  • Describing the potential of cell therapy as a treatment for Parkinson’s
  • 11:00 Morning Coffee

    11:20 TARGETING NEURODEGENERATIVE DISEASES

    Dr Thomas Weiser

    Dr Thomas Weiser, Senior Scientist, Department of CNS Research, Boehringer Ingleheim

  • Which mechanisms are important for neuronal function under physiological conditions?
  • What changes during neurodegenerative diseases?
  • Where can ion channel modulators be useful to fight neurodegeneration?
  • 12:00 NOVEL THERAPIES FOR ALZHEIMER'S

    Dr Patrick May

    Dr Patrick May, Head, Neuroscience Discovery Research, Eli Lilly

  • The implication of the beta amyloid peptide (Aß) as causative in Alzheimer's disease (AD)
  • How is the Aß peptide formed
  • Reducing Aß production by functionally inhibiting g-secretase both in cell and animal models of AD.
  • The in vivo and in vitro effects of these molecules
  • The potential usefulness of these molecules in the treatment of AD
  • 12:40 Networking Lunch

    14:00 NEURODEGENERATION INHIBITION AND REGENERATION

    Dr John Gillard

    Dr John Gillard, Chief Scientific Officer, Aegera

  • Targeting anti-apoptotic mechanisms in progressive neurodegenerative disorders like Parkinson’s, Alzheimer’s and Huntington’s disease
  • Small molecule approaches to: - mitochondrial apoptosis inhibition - signal transduction apoptosis inhibition - caspase inhibition
  • Regenerative strategies in post-apoptotic neurodegenerative conditions - stem cell transplantation - embryonic neuronal transplantation
  • Gene therapy in neurodegenerative models at Aegera Therapeutics - evidence from IAP transgenic models - NAIP and XIAP in adeno/adeno-associated viral vectors in apoptotic disorders of the CNS and eye
  • 14:20 Afternoon Tea

    14:40 TARGETING INTRACELLULAR MESSENGERS

    Dr Jeffry Vaught

    Dr Jeffry Vaught, President, Research and Development Division, Cephalon

  • What is the role of the MLK's and the Stress Activated Protein Kinase
  • Pathway in neuronal cell death
  • What is the preclinical rationale for utility in neurodegenerative disease
  • What is the clinical potential of this novel mechanism and impact on disease
  • 15:40 SPEAKER PANEL

    16:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.